NCT04775082
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 53 versions: 39 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 16, 2026 Show 6 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 9 words
- Enrollment target: estimated 78 to confirmed 82
- Secondary endpoints: 11 to 12
- Site details revised at 5 of 32 sites
- Publications: details revised at 1 of 1 entry
- Minor Study sites: 31 to 32
- Study completion date: Jan 15, 2027 to Feb 8, 2027
- Minor Study sites: 28 to 31v50
- Minor Study sites: 29 to 28v49
- Minor Study sites: 26 to 29v48
Show 34 earlier versionsHide 34 earlier versions
- Minor Publications: details revised at 1 of 1 entryv47
- Minor Study sites: 27 to 26v44
- Minor Study sites: 26 to 27v43
- Minor Study sites: 25 to 26v40
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 27 to 25
- Primary completion date changed from estimate of Jul 7, 2023 to Aug 1, 2023
- Study completion date: Jan 18, 2024 to Jan 15, 2027
- Minor Site details revised at 2 of 27 sitesv35
- Notable Trial status: Active, Not Recruiting to Recruiting
- Study sites: 26 to 27
- Minor Study completion date: Jan 4, 2024 to Jan 18, 2024
- Site details revised at 11 of 26 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 26 of 26 sites
- Minor Site details revised at 4 of 26 sitesv28
- Minor Site details revised at 1 of 26 sitesv27
- Minor Site details revised at 1 of 26 sitesv26
- Minor Study sites: 25 to 26v25
- Minor Site details revised at 2 of 25 sitesv24
- Minor Site details revised at 1 of 25 sitesv23
- Minor Study sites: 24 to 25v22
- Minor Site details revised at 1 of 24 sitesv21
- Minor Site details revised at 1 of 24 sitesv20
- Minor Site details revised at 1 of 24 sitesv19
- Minor Site details revised at 1 of 24 sitesv18
- Minor Study sites: 23 to 24v17
- Minor Site details revised at 1 of 23 sitesv16
- Minor Site details revised at 1 of 23 sitesv15
- Minor Site details revised at 1 of 23 sitesv14
- Minor Study sites: 22 to 23v13
- Minor Site details revised at 1 of 22 sitesv12
- Minor Study sites: 21 to 22v11
- Minor Site details revised at 2 of 21 sitesv10
- Minor Study sites: 19 to 21v9
- Minor Study sites: 17 to 19v8
- Minor Study sites: 16 to 17v7
- Minor Study sites: 13 to 16v6
- Minor Study sites: 12 to 13v5
- Minor Study sites: 11 to 12v4
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Relative Change in Body Mass Index (BMI)
Timeframe: Baseline (week 0), week 56
Secondary (12)
Relative Change in Body Weight (Percentage)
Percentage of Participants Achieving More Than or Equal to (≥) 5% Reduction of BMI
Change in Body Weight (Kilogram)
Change in BMI Standard Deviation Score (WHO.Int)
Percentage of Participants Achieving ≥10% Reduction of BMI
Show 7 moreShow less
Change in BMI Percentage of the 95th Percentile on Gender and Age-specific Growth Charts (CDC.Gov [CDC: {Centers for Disease Control and Prevention}])
Change in Waist Circumference
Change in Systolic Blood Pressure
Change in Diastolic Blood Pressure
Change in Glycated Haemoglobin (HbA1c)
Treatment Emergent Adverse Events (TEAEs)
Treatment Emergent Serious Adverse Events (SAEs)
Arms and interventions
Liraglutide 3.0 mgExperimental
The treatment duration is 56 weeks and the follow-up period is 26 weeks.
PlaceboPlacebo comparator
The treatment duration is 56 weeks and the follow-up period is 26 weeks.
Drugs: Liraglutide, Placebo
Sites
32 sites in 9 countries
United States 9, Portugal 8, Russia 4, Belgium 2, India 2, Israel 2, Malaysia 2, Switzerland 2, Mexico 1